Ionis rolls out promising PhIII data on volanesorsen for rare enzyme disorder, but safety questions linger
Ionis has nailed down positive Phase III data on its lead experimental drug volanesorsen, used to combat rare cases of familial chylomicronemia syndrome. But the biotech $IONS is still batting back questions about safety issues as it preps for filings with the FDA and EMA.
In the Phase III investigators reported a huge drop in triglycerides among the 33 FCS patients taking the drug, hitting the primary endpoint. The placebo arm saw the level of triglycerides go up, helping to illustrate the treatment effect.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
